Article: Negotiated Prices Take Effect for Ten Drugs in 2026

The Inflation Reduction Act (IRA) of 2022 created a new ability for Medicare to negotiate prices for the most expensive drugs the program covers. The first set of negotiated drug prices will take effect in 2026 and is estimated to save $1.5 billion in annual out-of-pocket costs for Medicare beneficiaries, while also saving the Medicare program $6 billion per year. Drugs selected for negotiation must be brand-name drugs that don’t have competition and must be among those that drive the most Medicare spending. The negotiated prices are a minimum of 38% off the 2023 list price. All eligible Medicare beneficiaries will have access to these prices, and new drugs will be added to the negotiated list each year.

These are the ten drugs for 2026: Eliquis, Entresto, Farxiga, Jardiance, Stelara, Enbrel, Imbruvica, Januvia, NovoLog, and Xarelto